Alaunos Therapeutics Files 8-K on Feb 16 Event
Ticker: TCRT · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**Alaunos Therapeutics filed a routine 8-K, signaling an administrative update, not a major operational change.**
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing indicates a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, with the company's business address listed as 2617 Bissonnet St Suite 225, Houston, TX 77005. The filing details are primarily administrative, confirming the company's identity and reporting obligations.
Why It Matters
This administrative filing ensures regulatory compliance and provides public notice of an event, maintaining transparency for investors regarding Alaunos Therapeutics, Inc.'s corporate actions.
Risk Assessment
Risk Level: low — The filing is administrative and does not disclose any events that would inherently increase or decrease risk.
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- February 16, 2024 (date) — Date of earliest event reported
- February 20, 2024 (date) — Filing date
- 2617 Bissonnet St Suite 225, Houston, TX 77005 (company) — Business address of Alaunos Therapeutics, Inc.
- 001-33038 (company) — Commission File Number for Alaunos Therapeutics, Inc.
FAQ
What is the purpose of this 8-K filing by Alaunos Therapeutics, Inc.?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, indicating an event reported on February 16, 2024, and filed on February 20, 2024.
What is the earliest event reported date in this filing?
The earliest event reported date in this filing is February 16, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on February 20, 2024.
What is the business address of Alaunos Therapeutics, Inc. as stated in the filing?
The business address of Alaunos Therapeutics, Inc. is 2617 Bissonnet St Suite 225, Houston, TX 77005.
What is the Commission File Number for Alaunos Therapeutics, Inc.?
The Commission File Number for Alaunos Therapeutics, Inc. is 001-33038.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-02-20 16:05:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TCRT Nasdaq Capital Market
- $1.00 b — as regained compliance with the minimum $1.00 bid price requirement, and otherwise sati
Filing Documents
- e619290_8k-at.htm (8-K) — 22KB
- 0001193805-24-000251.txt ( ) — 190KB
- tcrt-20240216.xsd (EX-101.SCH) — 3KB
- tcrt-20240216_lab.xml (EX-101.LAB) — 33KB
- tcrt-20240216_pre.xml (EX-101.PRE) — 22KB
- e619290_8k-at_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. By letter dated February 16, 2024, Alaunos Therapeutics, Inc. (the "Company") was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement, and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor for the one-year period through February 16, 2025.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALAUNOS THERAPEUTICS, INC. By: /s/ Michael Wong Michael Wong Vice President, Finance Date: February 20, 2024